A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options.
Recruiting
- Conditions
- neuroblastoma, children, relapsed, progressive
- Registration Number
- NL-OMON24917
- Lead Sponsor
- Academisch Medisch Centrum Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 66
Inclusion Criteria
1. Histological proven neuroblastoma;
2. Measurable primary and/or metastatic disease;
Exclusion Criteria
1. Received treatment within the last 21 days with an
investigational or conventional anti-cancer drug;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of efficacy as measured by response rate (and time-to-event measurements).
- Secondary Outcome Measures
Name Time Method Characterization of safety and toxicity profile.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie gemcitabine and 131I-MIBG synergy in neuroblastoma treatment?
How does gemcitabine-131I-MIBG combination compare to standard-of-care therapies for relapsed neuroblastoma?
Which biomarkers correlate with response to gemcitabine and 131I-MIBG in high-risk neuroblastoma?
What are the key adverse events associated with gemcitabine-131I-MIBG therapy in pediatric oncology?
Are there alternative radiolabeled compounds showing similar efficacy to 131I-MIBG in neuroblastoma?